Abraham M. Korman

Dr. Abraham M. Korman


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in JAAD Case Reports
Verified
Journal Article
Open access
LRLucy Rose
Lucy Rose
RKRachel Kirven
Rachel Kirven
KTKelly Tyler
Kelly Tyler
CCCatherine Chung
Catherine Chung
AKAbraham M. Korman
Abraham M. Korman

1 September 2022 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
KNKelsey B. Nusbaum
Kelsey B. Nusbaum
BDBrittany Dulmage
Brittany Dulmage
JCJennifer N. Choi
Jennifer N. Choi
SJSamantha M. Jaglowski
Samantha M. Jaglowski
AKAbraham M. Korman
Abraham M. Korman

7 February 2026 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
VSValerie R. Stichert
Valerie R. Stichert
BSBreanna Santoso
Breanna Santoso
BWBethany G. Winters
Bethany G. Winters
STSophia Thompson
Sophia Thompson
IAIsabelle Ayoub
Isabelle Ayoub
AKAbraham M. Korman
Abraham M. Korman
IgA vasculitis (IgAV) is classically associated with children, yet it is not uncommon in adults. Adult IgAV remains difficult to diagnose and manage because most existing criteria and therapeutic recommendations were developed for pediatric populations, leaving uncertainty around how to best diagnose and treat adult patients. To provide clinically useful, evidence-based guidance, we reviewed current literature on adult IgAV, including clinical features, diagnostic approaches, prognostic indicators, treatment strategies, and monitoring recommendations. Compared with pediatric cases, adults generally experience a more severe disease course, with higher rates of renal and gastrointestinal involvement, and greater risk of long-term morbidity. Diagnostic evaluation in adults is complicated by the lack of adult-specific diagnostic criteria and variable direct immunofluorescence findings. Prognostic analyses consistently identified renal and gastrointestinal involvement, older age, and medical comorbidities as predictors of adverse outcomes. Treatment evidence remains limited as randomized controlled trials are lacking. Monitoring recommendations emphasize prolonged renal follow-up as abnormalities may appear several months after initial presentation. Overall, adult IgAV constitutes a distinct clinical entity with greater severity and management challenges than pediatric disease, underscoring the need for dedicated adult-focused research and the development of standardized diagnostic and treatment guidelines.

1 October 2021 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
AKAbraham M. Korman
Abraham M. Korman
SFStephanie K. Fabbro
Stephanie K. Fabbro

14 July 2024 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
EHEmma Hansen
Emma Hansen
MGMatthew Gallardo
Matthew Gallardo
AYAllison Yan
Allison Yan
RMRohan Mital
Rohan Mital
DJDana Jolley
Dana Jolley
AKAbraham M. Korman
Abraham M. Korman

1 July 2024 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
EHEmma Hansen
Emma Hansen
RKRachel M. Kirven
Rachel M. Kirven
MGMatthew Gallardo
Matthew Gallardo
CCCatherine G. Chung
Catherine G. Chung
KFKristopher Fisher
Kristopher Fisher
AKAbraham M. Korman
Abraham M. Korman
This cohort study examines patients with drug reaction with eosinophilia and systemic symptoms who also have pustules.